Clinical Trials Logo

Filter by:
NCT ID: NCT05597397 Recruiting - Myopia Clinical Trials

Effect of Repeated Low-Level Red-Light Therapy on Retinal Function and Structure

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to evaluate the effect of repeated low-level red-light (RLRL) therapy on the retinal function and structure among myopic teenagers.

NCT ID: NCT05597384 Recruiting - Colorectal Cancer Clinical Trials

Assessment of Autologous Blood Marker Localization in Laparoscopic Colorectal Cancer Surgery

ABILITY
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Laparoscopic colorectal surgery has been proved to have similar oncological outcomes with open surgery. Due to the lack of tactile perception, surgeons may have misjudgments in laparoscopic colorectal surgery. Therefore, the accurate localization of a tumor before surgery is important, especially in the early stages of cancer. Recently, some retrospective studies reported the use of patients' autologous blood for preoperative colonic localization in colorectal cancer with successful detection by laparoscopy, but its benefits remain controversial. This study aimed to assess the accuracy and safety of autogenous blood marker localization in laparoscopic radical resection for colorectal cancer.

NCT ID: NCT05596981 Recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Start date: October 1, 2022
Phase:
Study type: Observational

This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD AML patients after allo-HSCT in terms of gut microbiome.

NCT ID: NCT05596968 Recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

Start date: October 1, 2022
Phase:
Study type: Observational

This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD positive AML patients after allo-HSCT in terms of gut microbiome.

NCT ID: NCT05596890 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

PICCRT
Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

Preoperative Immune checkpoint inhibitors combined with chemotherapy have revolutionized the treatment landscape of locally advanced esophageal squamous cell carcinoma. However, there are still a significant proportion of patients who could not benefit from such treatment modality. Currently, no effective biomarkers were identified to stratify responders and non-responders. Early dynamic and persistent relief of dysphagia may act as a predictive biomarker to reflect the on-treatment anti-tumor activity. In this prospective study, we aimed to explore the feasibility of using patient-reported outcomes (PROs) to predict the pathological complete response of esophageal squamous cell carcinoma patients treated with neoadjuvant immunochemotherapy with or without short-term radiation as well as to assess the efficacy and safety of short-term radiotherapy in PROs-insensitive patients after one cycle of neoadjuvant immunochemotherapy.

NCT ID: NCT05596630 Recruiting - Clinical trials for Carcinoma; Hepatocellular

Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC

Start date: May 8, 2023
Phase: N/A
Study type: Interventional

Primary liver cancer is one of the common malignant tumors in China, of which hepatocellular carcinoma (HCC) accounts for 85%-90%. It is worth noting that the recurrence rate of liver cancer is greater than 10% at 1 year after surgery, while the recurrence rate in 5 years reaches 70-80%. Stereotactic body radiation therapy (SBRT) refers to a kind of radiotherapy technology to achieve a steep dose gradient and achieve high-precision position and high-dose fractionated irradiation. The rapid dose drop-down enables SBRT to maximize the protection of normal tissues around the tumor, and it often requires only 1-5 times of high-dose fractionated irradiation to complete the course of treatment.SBRT may play an important role in the treatment of small intrahepatic recurrence HCC, but there is still a lack of evidence of high-level prospective studies. We intend to conduct a single-center, prospective, clinical study to further elaborate the efficacy and safety of SBRT in the treatment of small intrahepatic recurrent HCC.

NCT ID: NCT05596461 Recruiting - Affective Disorder Clinical Trials

New Techniques for Diagnosis and Treatment of Cognitive Impairment in Affective Disorder

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the pathological mechanism of cognitive impairment in patients with affective disorder based on brain gut axis research, preliminarily verify the clinical efficacy of new neural regulation technology on cognitive impairment, and establish an evaluation model to predict the efficacy of physical therapy for affective disorder.

NCT ID: NCT05596435 Recruiting - Pancreatic Cancer Clinical Trials

Early Detection of Pancreatic Cancer

Start date: October 10, 2022
Phase:
Study type: Observational

The purpose of this study is to enable non-invasive early detection of pancreatic cancer in high-risk populations through the establishment of a machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage pancreatic cancer patients and healthy individuals will be subjected to whole-genome sequencing. Features, such as cell-free DNA fragmentation, copy number variations and the status of KRAS gene mutation, will be assessed to generate this model.

NCT ID: NCT05596344 Recruiting - Depression Clinical Trials

Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors

Start date: May 20, 2023
Phase:
Study type: Observational

This study was a single-center prospective, real-world observational study with plans to enroll all eligible patients. The basic information, anxiety and depression, treatment and prognosis of these patients were collected.

NCT ID: NCT05596266 Recruiting - Clinical trials for T-cell Acute Lymphoblastic Leukemia

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

Start date: October 25, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractory/relapsed CD5+ T-ALL patients who have no available curative treatment options.